Phase 3 Study of SK-1403

PHASE3CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

December 17, 2019

Study Completion Date

December 21, 2019

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

SK-1403

Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.

DRUG

Placebo

Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.

Trial Locations (1)

Unknown

Investigational site (there may be other sites in this country), Tokyo

All Listed Sponsors
lead

Sanwa Kagaku Kenkyusho Co., Ltd.

INDUSTRY

NCT03801980 - Phase 3 Study of SK-1403 | Biotech Hunter | Biotech Hunter